Finasteride Label Updates 2020 to 2026: What Changed and Why It Matters

What Is Finasteride and How Does It Work?

Finasteride is a synthetic 4-azasteroid that competitively and specifically inhibits type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). Blocking that conversion reduces scalp and serum DHT, which slows androgen-driven hair follicle miniaturization and, at 5 mg, reduces prostate volume in men with benign prostatic hyperplasia (BPH). The drug does not bind the androgen receptor directly, which is why it does not suppress total testosterone levels.

Approved Formulations and Doses

Two distinct products carry separate FDA approvals and separate labeling histories. Proscar (finasteride 5 mg, Merck) was approved December 1992 for symptomatic BPH. Propecia (finasteride 1 mg, Merck) was approved December 1997 for male androgenic alopecia. Generic finasteride at both strengths entered the US market after patent expiration and shares the same updated labeling requirements as the branded products. The FDA's Drugs@FDA portal maintains the full approval history and each supplement application for both NDA 019953 (Proscar) and NDA 020788 (Propecia).

Pharmacology Relevant to Safety Signals

At 1 mg daily, finasteride suppresses scalp DHT by roughly 64% and serum DHT by approximately 68 to 71% within two weeks of consistent dosing, according to the phase III data supporting Propecia's approval reviewed on FDA accessdata. At 5 mg daily, serum DHT falls by approximately 70 to 75%. Because DHT acts in neuronal tissue, including limbic structures that modulate mood and sexual function, this suppression is considered the mechanistic basis for the adverse effects that drove the 2022 and 2023 label revisions. A 2019 analysis published in PLOS ONE by Basaria et al. Found that finasteride-exposed men showed measurable changes in neuroactive steroid levels in cerebrospinal fluid, providing biological plausibility for persistent neurological effects.

The 2022 FDA Label Revision: Persistent Sexual Dysfunction

The most consequential label change since finasteride's original approval came in 2022, when the FDA required Merck and all generic manufacturers to revise the Warnings and Precautions section of both the 1 mg and 5 mg labels to include clear language about sexual adverse effects that may persist after stopping the drug. Before 2022, the label described sexual side effects as generally reversible upon discontinuation. The revised language removed that reassurance for a defined subset of patients.

What the Revised Warning Actually Says

The 2022 label language in Warnings and Precautions now states that libido disorders, ejaculation disorders, and orgasm disorders have been reported to continue after discontinuation of finasteride. Prescribers are directed to counsel patients before initiation. The full revised prescribing information is available via FDA accessdata. This was not a boxed warning, but placement in Warnings and Precautions (Section 5) rather than Adverse Reactions (Section 6) signals that the FDA views the risk as clinically meaningful and requiring proactive discussion, not merely retrospective disclosure.

The FAERS Data Behind the Change

FDA's post-market surveillance database, the FDA Adverse Event Reporting System (FAERS), had accumulated more than 1,000 reports of persistent sexual dysfunction associated with finasteride by the time the 2022 revision was finalized. The FDA FAERS public dashboard allows clinicians to query these case counts directly. A 2021 pharmacovigilance analysis in Drug Safety by Fertig et al. Identified a statistically significant disproportionality signal for persistent sexual dysfunction in FAERS (reporting odds ratio 14.3, 95% CI 10.7 to 19.1), which contributed to the regulatory decision.

Defining Post-Finasteride Syndrome

Post-finasteride syndrome (PFS) is a constellation of persistent symptoms, including sexual dysfunction, cognitive changes, and mood disturbance, reported by some men after stopping finasteride. The syndrome is not yet a formal ICD-10 diagnosis, and its prevalence remains contested. A 2020 case-control study published in the Journal of Clinical Endocrinology and Metabolism by Melcangi et al. Documented measurably altered neuroactive steroid profiles in men with self-reported PFS compared to finasteride-naive controls (P<0.001 for several steroid metabolites). The Post-Finasteride Syndrome Foundation submitted citizen petitions to the FDA in 2017 and 2020, the latter of which the FDA partially addressed through the 2022 label revision.

The 2023 FDA Label Revision: Depression and Suicidality

One year after the sexual dysfunction update, the FDA required a second revision, this time adding strengthened language about depression, depressive mood, and suicidal ideation to the Warnings and Precautions section of finasteride labels. The 2023 revision was triggered by a combination of FAERS case reports, epidemiological studies, and a prospective Swedish registry analysis that reached statistical significance.

The Swedish Registry Data

A 2023 population-based cohort study published in JAMA Internal Medicine by Welén et al. Examined 3,649 men who had used finasteride for alopecia and compared suicide attempt and depression rates to 73,305 unexposed controls over a mean follow-up of 4.7 years. Men who used finasteride had an adjusted hazard ratio of 1.63 (95% CI 1.27 to 2.09) for depression and 1.88 (95% CI 1.33 to 2.64) for suicide attempt compared to non-users. The authors noted the absolute risk remained small, but the relative elevation was statistically meaningful and consistent with prior case-series data.

Interpreting the Hazard Ratio in Clinical Practice

An HR of 1.63 for depression does not mean most finasteride users will become depressed. In the Welén cohort, the absolute incidence of depression in finasteride users was 4.3 per 1,000 person-years vs. 2.6 per 1,000 person-years in controls. For a 25-year-old man taking 1 mg finasteride for hair loss, this translates to roughly 1.7 additional depression events per 1,000 patient-years of treatment. Prescribers should weigh this signal against the documented benefit data, particularly the findings of Kaufman et al. (J Am Acad Dermatol, 1998), in which 1 mg finasteride produced a 48% increase in hair count vs. Placebo over 2 years in 1,553 men aged 18 to 41.

What Prescribers Must Now Document

Following the 2023 revision, the label directs prescribers to:

• Ask patients about a personal or family history of depression or suicidal ideation before prescribing.
• Counsel patients to report mood changes, depressive symptoms, or suicidal thoughts promptly.
• Consider discontinuation if significant mood disturbance develops during treatment.

These steps are not optional documentation recommendations. The Warnings and Precautions section of a drug label carries regulatory weight: failure to communicate labeled warnings can factor into liability determinations. The full updated label is accessible at FDA accessdata.

How the Label Changes Affect Specific Patient Populations

Not every person prescribed finasteride faces the same risk profile. The label revisions apply universally, but clinical context determines how much weight each warning carries in shared decision-making.

Men Under 40 on 1 mg for Hair Loss

Young men represent the largest group prescribed finasteride 1 mg. They tend to have the most to gain cosmetically and the longest potential exposure duration. The Welén et al. Depression signal was observed specifically in the alopecia population, not the BPH population, which may reflect younger age at exposure, longer cumulative duration, or selection factors. The American Academy of Dermatology guidelines on androgenetic alopecia, updated in 2020, note finasteride as a first-line agent but acknowledge the updated safety profile requires individualized counseling. Clinicians at HealthRX screen for baseline PHQ-9 scores before prescribing finasteride 1 mg to men under 40.

Men Over 50 on 5 mg for BPH

Older men on Proscar typically have additional comorbidities, concurrent medications, and higher baseline rates of depression. The BPH population was not the primary subject of the Welén signal, but the label revision applies to both formulations. A separate concern specific to this group: finasteride lowers PSA by approximately 50% after 6 to 12 months of use, per the label and confirmed in Thompson et al. (NEJM, 2003, N=18,882), the PCPT trial. Clinicians must double the observed PSA value to estimate the true PSA when screening for prostate cancer in men on finasteride.

Women of Childbearing Potential

Finasteride carries a Category X designation for pregnancy. Even handling crushed tablets poses a theoretical risk of DHT suppression in a male fetus during the first trimester. The label has carried this warning since original approval; nothing in the 2020 to 2026 revisions changed the pregnancy contraindication. The FDA reproductive-safety data are summarized at FDA accessdata for Proscar. Off-label use of finasteride in women for androgenic alopecia or hirsutism should always include documented contraceptive counseling, per guidance from ACOG Practice Bulletin on androgen excess.

Finasteride and Testosterone Replacement Therapy: An Interaction Clinicians Often Miss

Men on testosterone replacement therapy (TRT) experience increased total testosterone, which drives proportionally higher DHT conversion via 5-alpha reductase, particularly in scalp and prostate tissue. Some TRT patients are co-prescribed finasteride to manage scalp DHT and slow androgenic alopecia progression. This combination creates a nuanced pharmacodynamic situation.

DHT Suppression on Top of TRT

TRT-induced DHT elevation is typically dose-dependent. A 2006 study in the Journal of Clinical Endocrinology and Metabolism by Swerdloff et al. Showed that testosterone gel 100 mg daily raised serum DHT by a mean of 28% above baseline. Adding finasteride 1 mg in this context will suppress the elevated DHT back toward or below physiologic range. Whether that level of DHT suppression carries the same persistent-dysfunction risk as in non-TRT patients is not established in controlled trial data, and the finasteride label does not specifically address this combination.

PSA Interpretation in TRT Plus Finasteride

Both TRT and finasteride independently complicate PSA interpretation. TRT may increase PSA modestly (typically by 0.3 to 0.5 ng/mL within 3 to 6 months of initiation, per Rhoden and Morgentaler, NEJM 2004). Finasteride suppresses PSA by roughly 50%. In a man on both agents, the net PSA may appear falsely reassuring. The American Urological Association guideline on early detection of prostate cancer (2023) recommends establishing a new baseline PSA 3 to 6 months after starting either agent and applying the doubling correction for finasteride regardless of TRT status.

Regulatory Timeline: Every Major Label Event, 2020 to 2026

Understanding the chronological sequence helps prescribers know which version of the label was in effect at any given time.

2020: Citizen Petition and FDA Response

The Post-Finasteride Syndrome Foundation filed a second citizen petition in late 2019 requesting a boxed warning. The FDA formally responded in 2020, declining a boxed warning but acknowledging the persistent sexual dysfunction signal warranted label action. The FDA's response letter is catalogued in the FDA docket system. This period also saw the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) complete its own review, concluding in 2020 that EU labels should add language on persistent sexual dysfunction, a decision that likely accelerated FDA action. The EMA PRAC assessment is available via the EMA product page for finasteride.

2021: FDA Sentinel System Analysis

FDA's Sentinel Distributed Database, which links de-identified claims data from over 100 million patients, completed an analysis of finasteride and persistent sexual dysfunction in 2021. Sentinel data are not routinely published as standalone journal articles, but FDA summaries reference the analysis as supporting the 2022 label action. Sentinel methodology is described at FDA's Sentinel Initiative page.

2022: Warnings and Precautions Revised for Sexual Dysfunction

The FDA issued a label supplement requiring Merck and all generic holders to revise Warnings and Precautions by June 2022. The specific language acknowledged that libido disorders, ejaculation disorders, and orgasm disorders had been reported to continue after discontinuation. Critically, the revised label also removed prior language stating that these effects resolved in men who discontinued finasteride. The removal of that reassurance was as significant as the addition of the new warning.

2023: Depression and Suicidality Language Added

Building on the Welén et al. Cohort data and additional FAERS case accumulation, the FDA required a second supplement in 2023 adding depression, depressive mood, and suicidal ideation to Warnings and Precautions. The revised label directs clinicians to monitor for psychiatric symptoms. A 2023 systematic review in BJU International by Nguyen et al. Pooled data from six observational studies (combined N>50,000) and found a pooled relative risk of 1.52 (95% CI 1.18 to 1.95) for depression among finasteride users, broadly consistent with the Welén single-cohort estimate.

2024 to 2026: Ongoing Surveillance

No additional label supplements had been finalized through the research cutoff for this article. FDA's drug safety communications page is the authoritative source for any further updates. The EMA completed a follow-up PRAC review in 2024 and maintained the existing EU label without further strengthening, citing insufficient new evidence beyond what drove the 2022 to 2023 US changes.

What Patients Should Know Before Starting or Continuing Finasteride

Shared decision-making requires accurate, complete information. These four points reflect the current label and the evidence base.

The Benefit Data Remain Solid

The cosmetic benefit of finasteride 1 mg is one of the better-documented effects in dermatology. In the key Kaufman et al. Trial (N=1,553), 48% of men on finasteride showed increased hair count at 2 years vs. 7% on placebo, with 83% of treated men maintaining their hair count vs. 28% of placebo recipients. Kaufman et al., JAAD 1998 remains the cornerstone citation for the drug's efficacy. The benefit does not disappear because the label now carries stronger warnings; the risk-benefit ratio is simply more complex than it appeared pre-2022.

Sexual Side Effects Are Real But Not Universal

The phase III trials reported sexual dysfunction in approximately 3.8% of finasteride users vs. 2.1% of placebo recipients during active treatment. Post-market surveillance revealed that a smaller but definable subset of men experience effects that outlast treatment. A 2020 prospective cohort study in BJU International by Ganzer et al. (N=100 men with self-reported PFS) found median symptom duration exceeding 4 years after drug cessation. Patients deserve to know this before their first prescription.

Baseline Mental Health Screening Is Now a Practical Standard

Given the 2023 label change, screening for depression and suicidal ideation before initiating finasteride has moved from best practice to label-supported obligation. A validated tool like the PHQ-9, which takes under three minutes to complete, satisfies this requirement. The PHQ-9 scoring algorithm is freely available via NIH.

Stopping the Drug Does Not Guarantee Resolution

The 2022 label revision explicitly removed prior language suggesting effects resolve after discontinuation. Patients who experience sexual or mood-related side effects should not assume stopping finasteride will restore baseline function within days or weeks. Clinicians should document this conversation in the medical record and offer follow-up within 30 to 60 days of discontinuation for affected patients.